Quotient Limited (QTNT) Stock Analysis
DELISTED 2022
What happened to Quotient Limited (QTNT) stock?
Quotient Limited (QTNT) no longer trades on public markets. It was delisted in December 2022. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Quotient Limited (QTNT) trades at $0.38. Quotient Limited is a commercial-stage diagnostics company focused on developing and marketing products for the global transfusion diagnostics market. Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for QTNT: QTNT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates QTNT against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
QTNT: 1/2 scored disciplines lean bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Quotient Limited (QTNT) Healthcare & Pipeline Overview
Quotient Limited develops and commercializes transfusion diagnostics, leveraging its innovative MosaiQ platform for immunohematology and serological disease screening. With a global presence and a focus on blood grouping solutions, Quotient serves hospitals, donor centers, and diagnostic companies, striving to enhance efficiency and accuracy in blood testing.
What Is the Investment Thesis for QTNT?
Quotient Limited presents a notable research candidate within the transfusion diagnostics market, driven by its innovative MosaiQ platform. The platform's ability to integrate multiple tests into a single process offers significant efficiency gains for blood banks and hospitals. Key value drivers include the successful commercialization and adoption of the MosaiQ platform, particularly the IH Microarray and SDS Microarray. Growth catalysts include expanding regulatory approvals for MosaiQ in key markets like the US and Europe, strategic partnerships with major blood banking organizations, and increasing market penetration in emerging economies. However, investors should be aware of potential risks, including competition from established players in the diagnostics market, regulatory hurdles, and the company's current negative profit margin of -324.9%. Successful execution of its commercialization strategy and achieving profitability are critical for long-term value creation.
Based on FMP financials and quantitative analysis
QTNT Key Highlights
Quotient Limited operates in the global transfusion diagnostics market, a critical sector within healthcare.
- The company's proprietary MosaiQ technology platform offers integrated immunohematology, serological disease screening, and molecular disease screening.
- Quotient's product portfolio includes conventional reagent products for blood grouping and a growing suite of MosaiQ-based microarrays.
- The company's gross margin stands at 38.8%, indicating potential for profitability with increased sales volume and operational efficiencies.
- Quotient serves a diverse customer base, including hospitals, donor collection agencies, and diagnostic companies, across the United States, France, Japan, and other international markets.
Who Are QTNT's Competitors?
QTNT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GRFS Grifols, S.A. is a global healthcare company focused on plasma-derived medicines and other innovative solutions. The company | $8.00 | +0.13% | $6.77B | 45 |
| OCDX Ortho Clinical Diagnostics Holdings plc | $17.63 | +0.92% | 46 | |
| ABT Abbott Laboratories | $116.64 | +2.19% | $202B | 70 |
| SYK Stryker Corporation | $329.45 | +0.53% | $126B | 79 |
| MDT Medtronic plc | $92.91 | +0.66% | $119B | 77 |
| BSX Boston Scientific Corporation | $50.37 | +2.03% | $74.9B | 80 |
| EW Edwards Lifesciences Corporation | $89.79 | -0.04% | $51.7B | 93 |
| DXCM DexCom, Inc. | $91.60 | +1.53% | $34.6B | 94 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are QTNT's Key Strengths?
Innovative MosaiQ platform for integrated blood testing.
- Comprehensive product portfolio covering blood grouping and disease screening.
- Global presence with sales in the United States, France, Japan, and other international markets.
- Strong focus on research and development.
What Are QTNT's Weaknesses?
Negative profit margin (-324.9%).
- Reliance on successful commercialization of the MosaiQ platform.
- Competition from established players in the diagnostics market.
- Dependence on regulatory approvals for product sales.
What Could Drive QTNT Stock Higher?
Regulatory approvals for MosaiQ platform in the United States and Europe.
- Expansion of MosaiQ platform into new applications, such as autoimmune diagnostics.
- Strategic partnerships with major blood banking organizations.
- Increasing adoption of automation in blood banks.
What Are the Key Risks for QTNT?
Competition from established players with greater resources.
- Regulatory hurdles and delays in product approvals.
- Negative profit margin and need to achieve profitability.
- Technological advancements that could render existing products obsolete.
What Are the Growth Opportunities for QTNT?
- Expansion of MosaiQ Platform: Quotient can expand the MosaiQ platform's capabilities by developing new assays and applications. The autoimmune microarray, COVID-19, and IH3 microarray represent opportunities to address unmet needs in diagnostics. Successful commercialization of these new microarrays could significantly increase revenue and market share.
- Strategic Partnerships: Forming strategic partnerships with major blood banking organizations and diagnostic companies can accelerate the adoption of the MosaiQ platform. Collaborations can provide access to established distribution networks, co-development opportunities, and increased market visibility. These partnerships can also help Quotient navigate regulatory hurdles and gain access to new markets. The timeline for realizing the benefits of these partnerships depends on the specific agreements and regulatory approvals.
- Geographic Expansion: Expanding into emerging markets, such as China and India, represents a significant growth opportunity for Quotient. These markets have a large and growing demand for transfusion diagnostics due to increasing healthcare spending and rising awareness of blood safety. Quotient can leverage its existing product portfolio and the MosaiQ platform to capture market share in these regions. The timeline for successful geographic expansion depends on regulatory approvals, market entry strategies, and local partnerships.
- Regulatory Approvals: Obtaining regulatory approvals for the MosaiQ platform in key markets, such as the United States and Europe, is crucial for driving adoption and revenue growth. FDA approval in the US and CE marking in Europe will allow Quotient to market its products to a wider customer base and compete more effectively with established players. The timeline for regulatory approvals depends on the specific products and the regulatory pathways involved.
- Increased Automation in Blood Banks: The increasing trend towards automation in blood banks presents a significant opportunity for Quotient. The MosaiQ platform's integrated design and high-throughput capabilities make it well-suited for automated workflows. By partnering with automation vendors and developing integrated solutions, Quotient can capitalize on this trend and increase its market share. The timeline for realizing this opportunity depends on the adoption rate of automation in blood banks and Quotient's ability to integrate its platform with existing automation systems.
What Are QTNT's Competitive Advantages?
- Proprietary MosaiQ platform: Offers a differentiated and integrated approach to blood testing.
- Specialized expertise: Deep knowledge and experience in transfusion diagnostics.
- Established customer relationships: Serves a diverse customer base in key markets.
- Regulatory approvals: Products are subject to regulatory oversight, creating barriers to entry.
What Does QTNT Do?
Quotient Limited, established in 2007 and headquartered in Eysins, Switzerland, is a commercial-stage diagnostics company dedicated to revolutionizing the global transfusion diagnostics market. The company's core focus lies in the development, manufacturing, and commercialization of products designed to improve the speed, efficiency, and accuracy of blood testing. Quotient's primary innovation is the MosaiQ platform, a proprietary technology designed for comprehensive, multi-analyte screening. This platform integrates immunohematology, serological disease screening, and molecular disease screening into a single, streamlined process. Quotient's product portfolio includes conventional reagent products for blood grouping, such as antisera products used to identify blood group antigens, reagent red blood cells for identifying blood group antibodies, whole blood control products for quality assurance, and ancillary products supporting blood grouping procedures. In addition to these conventional offerings, Quotient is actively developing a range of MosaiQ-based microarrays, including the MosaiQ SDS Microarray for serological disease screening (detecting cytomegalovirus and Syphilis), the MosaiQ MDS Microarray for molecular disease screening of donor red cells or source plasma, the MosaiQ IH Microarray for blood grouping, the MosaiQ Autoimmune Microarray, MosaiQ COVID-19, and the MosaiQ IH3 Microarray. Quotient distributes its products to a diverse customer base, including hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operations. The company's global reach extends to the United States, France, Japan, and other international markets, reflecting its commitment to serving the worldwide transfusion diagnostics community. Quotient's strategic focus on innovation and comprehensive screening solutions positions it as a key player in advancing the future of blood testing.
What Products and Services Does QTNT Offer?
- Develops and manufactures diagnostic products for the global transfusion diagnostics market.
- Commercializes and sells products for blood grouping and disease screening.
- Develops the MosaiQ platform, a proprietary technology for multi-analyte screening.
- Offers conventional reagent products for blood grouping, including antisera and reagent red blood cells.
- Provides microarrays for serological disease screening (SDS), molecular disease screening (MDS), and immunohematology (IH).
- Sells products to hospitals, donor collection agencies, and independent testing laboratories.
How Does QTNT Make Money?
- Develops and sells diagnostic products and platforms to hospitals, blood banks, and diagnostic labs.
- Generates revenue through the sale of reagent products, microarrays, and related consumables.
- Focuses on innovation and product development to expand its portfolio and market reach.
What Industry Does QTNT Operate In?
The global transfusion diagnostics market is characterized by increasing demand for accurate and efficient blood testing solutions. Key trends include the growing adoption of automation, the rising prevalence of infectious diseases, and the increasing complexity of blood banking procedures. Quotient Limited operates in a competitive landscape that includes established players like Grifols and Ortho Clinical Diagnostics. The company's MosaiQ platform offers a differentiated approach by integrating multiple tests into a single platform, potentially capturing market share by improving efficiency and reducing costs for blood banks and hospitals.
Who Are QTNT's Key Customers?
- Hospitals
- Donor collection agencies
- Independent testing laboratories
- Original equipment manufacturers
- Blood banking operations
Key Financial Metrics
Return on equity for Quotient Limited stands at 144.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -64.5%, showing how much profit it generates from its asset base. A current ratio of 3.10 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
Quotient Limited operates in the Medical - Devices industry within the Healthcare sector. The company is led by CEO Franz Walt. QTNT has traded publicly since 2014.
QTNT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Quotient's long-term prospects, signaling potential undervaluation.
- The social trading community is buzzing about Quotient's innovative MosaiQ platform and its potential to disrupt the diagnostics market.
- Positive sentiment in the community indicates belief that Quotient is strategically positioned to capitalize on growth opportunities.
- Market perception is shifting favorably as Quotient secures new partnerships, boosting investor confidence.
Bear Case
- Negative community sentiment highlights concerns about Quotient's debt levels and cash burn rate, raising questions about financial stability.
- Insider selling activity, even if for personal reasons, can create a perception of uncertainty among investors.
- Bearish views within the community focus on the competitive landscape and potential challenges in gaining market share.
- Market perception is sensitive to news about regulatory hurdles or delays in product approvals, which could impact Quotient's growth trajectory.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
QTNT Latest News
No recent news available for QTNT.
Leadership: Franz Walt
Chief Executive Officer
Franz Walt brings extensive experience in the diagnostics and life sciences industries to his role as CEO of Quotient Limited. Prior to joining Quotient, he held leadership positions at Roche Diagnostics, where he was responsible for various business areas, including near patient testing and point of care solutions. His career spans over two decades, with a focus on driving innovation, commercial excellence, and strategic growth in the healthcare sector. He has a proven track record of successfully launching new products and expanding market share in competitive environments.
Track Record: Since assuming the role of CEO, Franz Walt has focused on driving the commercialization of the MosaiQ platform and streamlining operations to improve efficiency. Key milestones under his leadership include securing regulatory approvals for MosaiQ in key markets and forging strategic partnerships to expand market reach. He has also overseen efforts to reduce operating costs and improve the company's financial performance, with the goal of achieving profitability in the long term.
What Investors Ask About Quotient Limited (QTNT) — Healthcare
What happened to Quotient Limited (QTNT) stock?
Quotient Limited (QTNT) no longer trades on public markets. It was delisted in December 2022. The figures below are historical and are not a current quote.
Can I still buy QTNT shares?
No. QTNT stopped trading on public markets in December 2022, so the shares are not available through a broker. Anything you see quoted for QTNT elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before QTNT stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Quotient Limited. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Quotient Limited do?
Quotient Limited is a diagnostics company focused on the global transfusion diagnostics market. It develops, manufactures, and commercializes products for blood grouping and disease screening, with a focus on its proprietary MosaiQ platform. This platform integrates immunohematology, serological disease screening, and molecular disease screening into a single, streamlined process.
What do analysts say about QTNT stock?
Analyst coverage of Quotient Limited is limited, but generally focuses on the potential of the MosaiQ platform to disrupt the transfusion diagnostics market. Key valuation metrics include revenue growth, gross margin, and cash burn. Analysts are closely watching the company's progress in securing regulatory approvals, expanding its product portfolio, and achieving profitability. However, the company's current financial performance and competitive landscape present challenges.
What are the main risks for QTNT?
The main risks for Quotient Limited include competition from established players in the diagnostics market, regulatory hurdles and delays in product approvals, and the company's current negative profit margin. The successful commercialization of the MosaiQ platform is critical for the company's long-term success, and any setbacks in this area could negatively impact its financial performance. Additionally, technological advancements could render existing products obsolete, requiring ongoing investment in research and development.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are based on the most recent available data.